Gluconorm P15 & P30  

Word Search (Top 10 - by date)

ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences (November 17, 2015)
CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies
CytomX Therapeutics (November 05, 2015)
RefleXion Medical Achieves Major Milestones in Development of Biologically-Guided Radiotherapy
RefleXion Medical (October 19, 2015)
MD Anderson, Theraclone Sciences form OncoResponse
The University of Texas MD Anderson Cancer Center (October 06, 2015)
ETView and The University of Texas MD Anderson Cancer Center (Houston, TX) Announce the Start of a Prospective, Randomized Clinical Evaluation of VivaSight-DL™ vs. Standard Double-Lumen Endotracheal Tubes
The University of Texas MD Anderson Cancer Center (September 21, 2015)
MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy
Cellectis (September 03, 2015)
Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
Merck & Co (August 13, 2015)
Concord Medical Acquires Additional Ownership Interest in MD Anderson Cancer Center Proton Therapy Center (August 12, 2015)
Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
Bristol-Myers Squibb (August 03, 2015)
Exact Sciences and MD Anderson Cancer Center Announce Partnership to Develop Screening and Diagnostic Tests for Lung Cancer
EXACT Sciences (June 04, 2015)

Displaying 10 out of a possible 73 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Gluconorm P15 & P30
Generic Name:   metformin hydrochloride; pioglitazone hydrochloride
Therapeutic Subcategory:     Anti-diabetics

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Gluconorm P15 & P30


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product:1 Gluconorm P15 & P30

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now